Nektar Therapeutics Q2 Loss increases, but beats estimates

Nektar Therapeutics (NKTR) released Loss for its second quarter that increased from last year but beat the Street estimates.

The company's earnings came in at -$159.07 million, or -$0.85 per share. This compares with -$125.52 million, or -$0.69 per share, in last year's second quarter.

Analysts on average had expected the company to earn -$0.94 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 23.8% to $21.59 million from $28.33 million last year.

Nektar Therapeutics earnings at a glance (GAAP) :

-Earnings (Q2): -$159.07 Mln. vs. -$125.52 Mln. last year.
-EPS (Q2): -$0.85 vs. -$0.69 last year.
-Analyst Estimate: -$0.94
-Revenue (Q2): $21.59 Mln vs. $28.33 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT